A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2002
12/12/2002	US20020188248 Needleless syringe using super sonic gas flow for particle delivery
12/12/2002	US20020188107 Plant protein for use in the treatment of cancer
12/12/2002	US20020188106 Tau protein epitopes for use in the treatment of alzheimer's disease
12/12/2002	US20020187993 Bifunctional energy-reversible acyl-compositions
12/12/2002	US20020187992 Prodrugs via acylation with cinnamate
12/12/2002	US20020187947 Inflammation-related gene
12/12/2002	US20020187946 Mammalian iap gene family, primers, probes and detection methods
12/12/2002	US20020187925 Vaccines; immunology response
12/12/2002	US20020187472 Nucleotide sequences coding protein for use in the treatment of cancer
12/12/2002	US20020187471 Novel telomerase
12/12/2002	US20020187466 Detection of infections in humans; obtain sample, incubate with antibody, detect signal, presence of signal indicates infection
12/12/2002	US20020187204 Diet composition and method of weight management
12/12/2002	US20020187163 Herpes simplex virus comprising a mutation within the BstEII-EcoNI fragment of the BamHI x fragment of said virus; cancer vaccine
12/12/2002	US20020187161 H. pylori antigens
12/12/2002	US20020187160 Vaccine delivery system
12/12/2002	US20020187159 The use of heat shock protein 70 preparations in vaccination against cancer and infectious disease
12/12/2002	US20020187158 An allergenic protein which derivative has a reduced allergenic activity compared with the allergenic protein from which it is derived, e.g., Bet v 1, for the treatment or prevention of an allergic disorder
12/12/2002	US20020187157 Administering an amyloidogenic polypeptide or subsequence thereof to induces production of antibodies against the amyloidogenic polypeptide; treatment of Alzheimer's disease
12/12/2002	US20020187156 Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
12/12/2002	US20020187155 Ringworm vaccine
12/12/2002	US20020187154 Detoxified mutant A subunit or detoxified mutant holotoxin of pertussis toxin (PT) or Pseudomonas endotoxin A, wherein the antigen is not the detoxified mutant.
12/12/2002	US20020187152 Administering a drug which can selectively kill Fusobacterium varium cells, or a drug which can neutralize the toxin produced by Fusobacterium varium cells; vaccines, diagnosis, screening
12/12/2002	US20020187150 Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
12/12/2002	US20020187149 Activity-inhibiting amount of a growth factor neutralising agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptible carrier.
12/12/2002	US20020187148 T cell receptor ligands and methods of using same
12/12/2002	US20020187147 Antigen specific recombinant MHC class II molecules and methods of use
12/12/2002	US20020187145 Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
12/12/2002	US20020187144 Useful for treating patients with colorectal cancer and gastric carcinomas; particularly useful for treating patients who have tumors that are resistant to one or more chemotherapeutic agents and/or have metastasized.
12/12/2002	US20020187141 Composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent; determination whether the failure of traditional chemotherapy is due to multidrug resistant tumor cells
12/12/2002	US20020187135 Methods for inducing antigen-specific t cell tolerance
12/12/2002	US20020187131 Conjugating an antigen to a molecule targeted to an endocytic receptor on the dendritic cell, such as DEC-205. The molecule targeted may be a natural ligand to the receptor or an antibody thereto.
12/12/2002	US20020187129 Adeno-associated virus materials and methods
12/12/2002	US20020187105 Polymer combinations that result in stabilized aerosols for gene delivery to the lungs
12/12/2002	CA2830887A1 Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
12/12/2002	CA2457959A1 Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
12/12/2002	CA2449770A1 Novel anti-infectives
12/12/2002	CA2449715A1 Peptides for chlamydophila pneumoniae vaccine and diagnosis
12/12/2002	CA2449670A1 Mutant forms of cholera holotoxin as an adjuvant
12/12/2002	CA2449663A1 Mutant forms of cholera holotoxin as an adjuvant
12/12/2002	CA2449658A1 Use of rank antagonists to treat cancer
12/12/2002	CA2449482A1 Chds as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449479A1 Map3ks as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449425A1 Slc2as as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449289A1 Gfats as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449281A1 Prmts as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449275A1 Dgks as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449270A1 Pibs as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449267A1 Hs2sts as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449206A1 Cads as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449136A1 Igs as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449135A1 Adsls as modifiers of the p53 pathway and methods of use
12/12/2002	CA2448824A1 Novel compounds for chemiluminescense procedures
12/12/2002	CA2448444A1 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
12/12/2002	CA2448427A1 Molecules and methods for inhibiting shedding of kim-1
12/12/2002	CA2448282A1 Slc7s as modifiers of the p53 pathway and methods of use
12/12/2002	CA2448256A1 Novel human proteins, polynucleotides encoding them and methods of using the same
12/12/2002	CA2448250A1 Limks as modifiers of the p53 pathway and methods of use
12/12/2002	CA2448112A1 Lces as modifiers of the p53 pathway and methods of use
12/12/2002	CA2448107A1 Marks as modifiers of the p53 pathway and methods of use
12/12/2002	CA2448073A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/12/2002	CA2447935A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
12/12/2002	CA2447695A1 Modified antibodies to prostate-specific membrane antigen and uses thereof
12/11/2002	EP1264890A2 Plasmodium vivax blood stage antigens, antibodies, and diagnostic assays
12/11/2002	EP1264612A1 Method for nasal application of a medicinal substance
12/11/2002	EP1264600A1 Immune enhancement compositions and use thereof
12/11/2002	EP1263965A2 Avirulent, immunogenic flavivirus chimeras
12/11/2002	EP1263960A2 Anti-tissue factor antibodies with enhanced anticoagulant potency
12/11/2002	EP1263959A1 Antibodies to human cd154
12/11/2002	EP1263955A2 Polypeptides and nucleic acids encoding same
12/11/2002	EP1263954A2 Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis
12/11/2002	EP1263948A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/11/2002	EP1263936A1 Altered strain of the modified vaccinia virus ankara (mva)
12/11/2002	EP1263928A1 Cytotoxic t lymphocytes activated by dendritic cell hybrids
12/11/2002	EP1263791A2 Human g-protein chemokine receptor (ccr5) hdgnr10
12/11/2002	EP1263789A2 Antibody inhibiting the binding between gp120 and dc-sign and screening methods
12/11/2002	EP1263787A2 G-protein coupled receptors
12/11/2002	EP1263786A2 Methods and compositions for immunoregulation
12/11/2002	EP1263784A1 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes
12/11/2002	EP1263781A1 Viral antigen and vaccine against isav (infectious salmon anaemia virus)
12/11/2002	EP1263780A2 Liv-1 related protein, polynulceotides encoding the same and use thereof for treatment of cancer
12/11/2002	EP1263779A1 Self antigen vaccines for treating b cell lymphomas and other cancers
12/11/2002	EP1263776A2 Peptides targeting specifically tumor-derived endothelial cells
12/11/2002	EP1263775A1 Hla binding peptides and their uses
12/11/2002	EP1263484A1 Coating which promotes endothelial cell adherence
12/11/2002	EP1263464A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function
12/11/2002	EP1263463A1 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cells
12/11/2002	EP1263462A1 Human herpesvirus 6a and 6b transfer factors for the treatment of chronic fatigue syndrome and multiple sclerosis
12/11/2002	EP1263461A1 Adenovirus formulations
12/11/2002	EP1263456A2 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia"
12/11/2002	EP1263448A1 Maca and antler for augmenting testosterone levels
12/11/2002	EP1263446A2 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
12/11/2002	EP1263432A1 Use of compatible solutes as inhibitors of the enzymatic decomposition of macromolecular biopolymers
12/11/2002	EP1263430A2 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases
12/11/2002	EP1263410A1 Urogenital or anorectal transmucosal vaccine delivery system
12/11/2002	EP0835131B1 cDNA CLONE FOR SOUTH AFRICAN ARBOVIRUS NO. 86
12/11/2002	EP0802985B1 Cell cycle regulated repressor and dna element
12/11/2002	EP0713397B1 Vaccine containing live virus
12/11/2002	EP0591431B1 Hepatitis c virus (hcv) polypeptides
12/11/2002	CN1384884A Herpes virus vectors for dendritic cells
12/11/2002	CN1384883A Production of recombinant respiratory syncytical viruses expressing immune modulatory molecules

1 ... 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 ... 1823